Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The Boston-based biotech has secured a substantial new investment for its protein degradation platform which has the potential to treat currently undruggable cancers in a new way.
We are delighted to announce the shortlist for the 16th Annual Scrip Awards.
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Hopes that the Phase II TAURIEL trial could potentially validate the anti-tau antibody approach to treating Alzheimer's have been dashed as semorinemab did not meet its endpoints.
Company is confident that data readout from pivotal trial could be ready before the end of 2020.
Sanofi/Regeneron’s anti-PD-1 product Libtayo may be late to the NSCLC party but strong data from EMPOWER-Lung 1 suggest it could gain traction in the space, especially in patients with high PD-L1 expression levels.
The Dutch biotech's C-suite tells Scrip that the technology it has developed and now licensed to Genentech allows it to systematically go through the whole genome gene by gene and discover what the modifier of a particular disease is.
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.